Cytori Therapeutics Inc. (CYTX) Stock Price Up 3.9%
Cytori Therapeutics Inc. (NASDAQ:CYTX) rose 3.9% during mid-day trading on Friday . The company traded as high as $2.16 and last traded at $2.13, with a volume of 318,286 shares changing hands. The stock had previously closed at $2.05.
CYTX has been the subject of a number of recent analyst reports. Maxim Group restated a “buy” rating and issued a $5.00 target price on shares of Cytori Therapeutics in a report on Wednesday, July 20th. Zacks Investment Research upgraded shares of Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a report on Tuesday, July 12th. Finally, Roth Capital restated a “buy” rating and issued a $11.00 target price on shares of Cytori Therapeutics in a report on Tuesday, June 28th.
The firm’s market cap is $28.93 million. The firm’s 50-day moving average price is $2.06 and its 200 day moving average price is $2.82.
Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.03) by $0.38. During the same period last year, the firm earned ($0.07) earnings per share. The business had revenue of $2.90 million for the quarter, compared to the consensus estimate of $2.05 million. The company’s revenue was up 26.1% compared to the same quarter last year. Equities analysts predict that Cytori Therapeutics Inc. will post ($1.59) EPS for the current year.
Cytori Therapeutics, Inc (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.